Literature DB >> 25496816

L-carnitine Reduces Muscle Cramps in Patients With Cirrhosis.

Hiroyuki Nakanishi1, Masayuki Kurosaki1, Kaoru Tsuchiya1, Natsuko Nakakuki1, Hitomi Takada1, Shuya Matsuda1, Kouichi Gondo1, Yu Asano1, Nobuhiro Hattori1, Nobuharu Tamaki1, Shoko Suzuki1, Yutaka Yasui1, Takanori Hosokawa1, Jun Itakura1, Yuka Takahashi1, Namiki Izumi2.   

Abstract

We performed a prospective study to evaluate the ability of L-carnitine, which is involved in the β-oxidation of fatty acids, to reduce muscle cramps in patients with cirrhosis. Consecutive patients with cirrhosis and muscle cramps were given L-carnitine 300 mg, 3 times/day (900 mg/day, n = 19) or 4 times/day (1200 mg/day, n = 23) for 8 weeks. The frequency of muscle cramps was assessed by questionnaires, and the degree of muscle cramping was assessed by using the visual analogue scale (VAS). Muscle cramping was reduced in 88.1% of all subjects at the end of the 8-week study period and disappeared for 28.6% of patients. Overall VAS scores decreased significantly from 69.9 ± 22.5 at baseline to 26.2 ± 29.1 after 8 weeks (P < .0001). The dose of L-carnitine was significantly associated with percentages of patients with reduced muscle cramps after 8 weeks (43.5% in the 1200 mg/day group vs 10.5% in the 900 mg/day group, P = .037) and VAS scores at 8 weeks (9.9 ± 13.5 in the 1200 mg/day group vs 39.6 ± 31.9 in the 900 mg/day group, P = .003). No adverse events were reported. Therefore, L-carnitine appears to be safe and effective for reducing liver cramps in patients with cirrhosis.
Copyright © 2015 AGA Institute. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Clinical Trial; Fatty Acid; Lipid Metabolism; Liver Fibrosis

Mesh:

Substances:

Year:  2014        PMID: 25496816     DOI: 10.1016/j.cgh.2014.12.005

Source DB:  PubMed          Journal:  Clin Gastroenterol Hepatol        ISSN: 1542-3565            Impact factor:   11.382


  18 in total

1.  CPT2 downregulation adapts HCC to lipid-rich environment and promotes carcinogenesis via acylcarnitine accumulation in obesity.

Authors:  Naoto Fujiwara; Hayato Nakagawa; Kenichiro Enooku; Yotaro Kudo; Yuki Hayata; Takuma Nakatsuka; Yasuo Tanaka; Ryosuke Tateishi; Yohko Hikiba; Kento Misumi; Mariko Tanaka; Akimasa Hayashi; Junji Shibahara; Masashi Fukayama; Junichi Arita; Kiyoshi Hasegawa; Hadassa Hirschfield; Yujin Hoshida; Yoshihiro Hirata; Motoyuki Otsuka; Keisuke Tateishi; Kazuhiko Koike
Journal:  Gut       Date:  2018-02-06       Impact factor: 23.059

Review 2.  Sarcopenia in chronic liver disease: mechanisms and countermeasures.

Authors:  Sophie L Allen; Jonathan I Quinlan; Amritpal Dhaliwal; Matthew J Armstrong; Ahmed M Elsharkawy; Carolyn A Greig; Janet M Lord; Gareth G Lavery; Leigh Breen
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2020-11-25       Impact factor: 4.052

3.  Current status of primary liver cancer and decompensated cirrhosis in Japan: launch of a nationwide registry for advanced liver diseases (REAL).

Authors:  Kazuya Okushin; Ryosuke Tateishi; Arata Takahashi; Koji Uchino; Ryo Nakagomi; Takuma Nakatsuka; Tatsuya Minami; Masaya Sato; Mitsuhiro Fujishiro; Kiyoshi Hasegawa; Yuichiro Eguchi; Tatsuya Kanto; Shoji Kubo; Hitoshi Yoshiji; Hiroaki Miyata; Namiki Izumi; Masatoshi Kudo; Kazuhiko Koike
Journal:  J Gastroenterol       Date:  2022-07-05       Impact factor: 6.772

Review 4.  Treatment of Muscle Cramps in Patients With Cirrhosis of Liver: A Systematic Review.

Authors:  Shivam Kalia; Preetam Nath; Mona Pathak; Anil C Anand
Journal:  J Clin Exp Hepatol       Date:  2021-11-02

5.  Impact of L-carnitine on imatinib-related muscle cramps in patients with gastrointestinal stromal tumor.

Authors:  Heejung Chae; Min-Hee Ryu; Jungeun Ma; Moyeol Beck; Yoon-Koo Kang
Journal:  Invest New Drugs       Date:  2019-10-18       Impact factor: 3.850

6.  Effect of L-Carnitine in Patients With Liver Cirrhosis on Energy Metabolism Using Indirect Calorimetry: A Pilot Study.

Authors:  Yoshiyuki Sakai; Hiroki Nishikawa; Hirayuki Enomoto; Kazunori Yoh; Yoshinori Iwata; Kunihiro Hasegawa; Chikage Nakano; Kyohei Kishino; Yoshihiro Shimono; Ryo Takata; Takashi Nishimura; Nobuhiro Aizawa; Naoto Ikeda; Tomoyuki Takashima; Akio Ishii; Hiroko Iijima; Shuhei Nishiguchi
Journal:  J Clin Med Res       Date:  2016-10-26

7.  Prognostic significance of nonprotein respiratory quotient in patients with liver cirrhosis.

Authors:  Hiroki Nishikawa; Hirayuki Enomoto; Yoshinori Iwata; Kyohei Kishino; Yoshihiro Shimono; Kunihiro Hasegawa; Chikage Nakano; Ryo Takata; Akio Ishii; Takashi Nishimura; Kazunori Yoh; Nobuhiro Aizawa; Yoshiyuki Sakai; Naoto Ikeda; Tomoyuki Takashima; Hiroko Iijima; Shuhei Nishiguchi
Journal:  Medicine (Baltimore)       Date:  2017-01       Impact factor: 1.889

8.  L-Carnitine Suppresses Loss of Skeletal Muscle Mass in Patients With Liver Cirrhosis.

Authors:  Masatsugu Ohara; Koji Ogawa; Goki Suda; Megumi Kimura; Osamu Maehara; Tomoe Shimazaki; Kazuharu Suzuki; Akihisa Nakamura; Machiko Umemura; Takaaki Izumi; Naoki Kawagishi; Masato Nakai; Takuya Sho; Mitsuteru Natsuizaka; Kenichi Morikawa; Shunsuke Ohnishi; Naoya Sakamoto
Journal:  Hepatol Commun       Date:  2018-08-06

Review 9.  Liver Cirrhosis: Evaluation, Nutritional Status, and Prognosis.

Authors:  Hiroki Nishikawa; Yukio Osaki
Journal:  Mediators Inflamm       Date:  2015-09-30       Impact factor: 4.711

Review 10.  Evidence-based clinical practice guidelines for Liver Cirrhosis 2020.

Authors:  Hitoshi Yoshiji; Sumiko Nagoshi; Takemi Akahane; Yoshinari Asaoka; Yoshiyuki Ueno; Koji Ogawa; Takumi Kawaguchi; Masayuki Kurosaki; Isao Sakaida; Masahito Shimizu; Makiko Taniai; Shuji Terai; Hiroki Nishikawa; Yoichi Hiasa; Hisashi Hidaka; Hiroto Miwa; Kazuaki Chayama; Nobuyuki Enomoto; Tooru Shimosegawa; Tetsuo Takehara; Kazuhiko Koike
Journal:  J Gastroenterol       Date:  2021-07-07       Impact factor: 7.527

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.